Rare Diseases
🇪🇺 EMA Page 3EMA news and analysis for pharmaceutical BD, investment, and market access · 7 articles on this page
Gain critical insights into global orphan drug development & rare disease market trends. Stay ahead in pharma R&D, investment, and regulatory strategy.
Showing 25–31 of 31 articles
Real-World Evidence EU Drug Development: EMA's Hybrid Trial Framework
AIM ImmunoTech Advances Ampligen to Phase 3 Pancreatic Cancer Trial with Orphan Drug Status
AB Science Secures €25 Million Clinical Trial Insurance for Masitinib ALS Phase III Study
MeiraGTx Acquires Botaretigene Sparoparvovec Gene Therapy from Johnson & Johnson for X-linked Retinitis Pigmentosa Treatment
AI Drug Discovery EU: Accelerating Rare Disease Therapies via COMP & EMA
EU Clinical Trials Regulation 2026: Impact on Rare Disease Drug Development
Orphan Drug Pricing EU: Market Analysis and Reimbursement Trends